Heidi Mansour

Heidi Mansour

Associate Professor, BIO5 Institute
Associate Professor, Clinical Translational Sciences
Associate Professor, Medicine
Associate Professor, Pharmaceutical Sciences
Primary Department
(520) 626-2768

Research Interest

Research Interest

Dr. Heidi M. Mansour, Ph.D., R.Ph. is a Tenured Associate Professor of Pharmaceutical Sciences in the College of Pharmacy with joint faculty appointments in the BIO5 Research Institute, the Clinical Translational Sciences graduate program in the UAHS, and the College of Medicine in the Division of Translational and Regenerative Medicine at The University of Arizona (UA) in Tucson, Arizona (USA). Dr. Mansour has a faculty member affiliation in the UA Institute of the Environment and is a research member the UA NCI Comprehensive Cancer Center Therapeutic Development Program. Dr. Mansour is Director of Pharmaceutics and Pharmacokinetics and Director of the Pharm.D./Ph.D. Dual Degree Program. She lectures in the B.S. Pharmaceutical Sciences undergraduate program, the Pharm.D. professional program and in the Pharmaceutics and Pharmacokinetics track of the graduate program at The University of Arizona. In addition to teaching, Dr. Mansour serves as Faculty Advisor in the Pharm.D./Ph.D. Dual-Degree Joint Program and Director of the Pharmaceutics and Pharmacokinetics track in the Pharmaceutical Sciences graduate program in The UA College of Pharmacy. As PI on multiple NIH, NSF, FDA, and pharmaceutical industrial grants, Dr. Mansour successfully leads multiple cutting-edge research projects. Her innovative research program has produced Assistant Professors who are employed at major research universities in the United States and in the Republic of S. Korea. In addition, her research program has produced Senior Research Scientists who are employed in major pharmaceutical companies in the United States. As Postdoc Mentor, Dr. Mansour has successfully mentored and trained over 10 Postdoctoral Research Scholars in my research program. As Major Professor, Dr. Mansour has successfully trained and graduated 3 doctoral graduate students with PhD degrees. Her mentoring experience extends as an active faculty mentor in the ATS Assembly Mentorship Program for several mentees in the ATS Assemblies each year. Dr. Mansour has published over 80 peer-reviewed scientific journal papers, 13 book chapters, 2 edited books, and over 100 scientific conference abstracts. She serves on the Editorial Advisory Boards of the The Royal Society of Chemistry Molecular Systems Design & Engineering, APhA/FIP Journal of Pharmaceutical Sciences, and Pharmaceutical Technology. Research in the Mansour GLP-approved labs focuses on the design, development, and optimization of advanced drug delivery systems and drug dosage forms. A systematic Quality-by-Design (QbD) approach includes in silico computational molecular modeling for predictive drug and formulation modeling, comprehensive physicocharacterization, advanced microscopy imaging, design of experiments (DOEs), formulation, USP/FDA-required in vitro performance studies, in vitro cellular studies, in vivo rodent animal studies for pharmacokinetics/pharmacodynamics/drug biodistribution, and translation medicine experiments. Dr. Mansour is an annual Faculty Instructor at ISAM (International Society of Aerosols in Medicine) Aerosol School, instructor in two online webinars on inhalation aerosol drug delivery, and instructor in Buchi Advanced Spray Drying short-courses. She was recently Co-Chair of the Drug Delivery: New Devices & Emerging Therapies Group in the International Society of Aerosols in Medicine (ISAM), and has been an expert member of NIH NICHD U.S. Pediatric Formulations Initiative New Drug Delivery Systems Aerosols Working Group for several years. Dr. Mansour currently serves on the Drug/Device Discovery and Development (DDDD) Committee of the American Thoracic Society (ATS). She regularly serves as an expert reviewer for scientific journals and grant funding agencies including NIH study sections, Department of Defense (DOD) study panels, National Science Foundation (NSF) study panels, AAAS, Catalent Drug Delivery Institute and international funding agencies such as the German-Israeli Foundation, German International Exchange Service (DAAD), Cochrane Airways Group of the National Health Service (London, England), Engineering and Physical Sciences Research Council (London, England), PRESTIGE Postdoc Fellowship Programme of the European Commission (Paris, France), and the Biomedical Innovation Program of the French National Research Agency (Paris, France). In addition to serving on NSF study panels, NIH study sections, and international study panels in the European Union and Great Britain, her innovative research program continuously attracts competitive funding awards from federal sources (NIH, NSF, FDA, DOD) and the pharmaceutical industry. In addition to lecturing in the BS Pharmaceutical Sciences undergraduate, Ph.D. graduate, and Pharm.D. professional programs, Dr. Mansour leads her research labs where she trains postdoctoral scholars, visiting scholars, visiting professors, graduate students, Pharm.D. student researchers, and physician-scientist (MD/PhD) fellows. As Major Professor and mentor, her research program has successfully graduated several Ph.D.s. Her innovative research program has produced Assistant Professors employed at research universities in the United States and in the Republic of S. Korea and Senior Research Scientists employed at major pharmaceutical companies in the United States. Dr. Mansour is an active, long-time member of several scientific organizations and elected member to honor societies, including the Sigma Xi Scientific Research Honor Society, Rho Chi Pharmaceutical Honor Society, and Golden Key International Honor Society. As a registered pharmacist for over 20 years, she earned her BS in pharmacy with honors and distinction, a PhD minor in advanced physical and interfacial chemistry (Department of Chemistry), and a PhD major in drug delivery/pharmaceutics (School of Pharmacy) from the University of Wisconsin-Madison. Also at the U.W.-Madison, she had been a Clinical Instructor for a few years. Having completed postdoctoral fellowships at the U.W.-Madison and at the University of North Carolina-Chapel Hill, she was awarded the UNC-Chapel Hill Postdoctoral Award for Research Excellence from the Office of the Vice-Chancellor, the AAPS Postdoctoral Fellow Award in Research Excellence, and the PhRMA Foundation Postdoctoral Fellowship award. As an Instructor, she served on the Graduate Faculty at UNC-Chapel Hill.


de la Vega, M. R., Dodson, M., Gross, C., Manzour, H., Lantz, R. C., Chapman, E., Wang, T., Black, S. M., Garcia, J. G., & Zhang, D. D. (2016). Role of Nrf2 and Autophagy in Acute Lung Injury. Current pharmacology reports, 2(2), 91-101.
BIO5 Collaborators
Clark Lantz, Heidi Mansour

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are: increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.

Hayes, D., Black, S. M., Tobias, J. D., Mansour, H. M., & Whitson, B. A. (2015). Influence of pulmonary hypertension on survival in advanced lung disease. Lung [Impact Factor: 2.271], 193(2), 213-21.

Effects of pulmonary hypertension (PH) in advanced lung disease remain unclear.

Mansour, H. (2015). Aerosol Medicine.. Pan European Networks: Science & Technology, 16, 1-2.

Aerosol Medicine. Pan European Networks: Science & Technology (2015) 16:1-2.

Duan, J., Vogt, F. G., Xiaojian, L. i., Hayes, D., & Mansour, H. M. (2013). Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. International journal of nanomedicine (Impact Factor: 4.195), 8, 3489-3505.

PMID: 24092972;PMCID: PMC3787929;Abstract:

The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX:DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/ nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX:DPPC inhalation powders. © 2013 Duan et al.

Hayes, D., Black, S. M., Tobias, J. D., Kirkby, S., Mansour, H. M., & Whitson, B. A. (2016). Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation. The Annals of thoracic surgery, 101(1), 246-52.

The influence of varying levels of pulmonary hypertension (PH) on survival in idiopathic pulmonary fibrosis is not well defined.